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definitive RT/CT. Further treatment intensification for 
patients with relative SUV >0.57 seems justified.  
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Purpose/Objective: 
Introduction: In literature a lower survival in a larger GTV 
was found in a retrospective analysis of a prospective 
database of 270 patients (Dehing-Oberije). These patients 
were treated with (chemo) radiotherapy for NSCLC. This 
raises the question to specify the GTV and the PTV further 
with a cutoff point in our own database with patients treated 
with CCRT for locally advanced NSCLC. 
Purpose: Is the GTV a better predictor of outcome of 
treatment (LC, LRC, DFS, OS) than the PTV? Can we find a 
cut-off with the inclusion of the volume prediction (GTV or 
PTV) to use the least toxic treatment with the same or better 
result for patients with locally advanced non-small cell lung 
carcinoma (NSCLC)? 
Materials and Methods: In 132 patients (PET-CT staged) 
treated with CCRT for locally advanced non-small cell lung 
carcinoma in the period 2005-2012, one observer delineated 
the GTV of the primary tumor and lymph nodes and the 
volume (cc) was calculated. The planning target volume 
(PTV) was generated, prognostic factors and outcome 
registered retrospectively. The Cox regression model and 
multivariate support will be calculated and the difference 
will be tested. The median volume (GTV and PTV) cutoff 
applied and tested separately for consistency in the spline 
predict model. 
Results: In the univariate analysis GTV (>77 cc) (p=0,031/HR 
1.9), PTV (>390 cc) (p=0.0035/HR 2,4) and gender 
(p<0,001/HR 0.3) are significantly favorable prognostic 
factors for overall survival (OS). In the multivariate cox-
regression analysis PTV >390 cc (p=0.012/HR 2,5) and gender 
(p=0,006/HR 0.35) (male: female) but not GTV are 
significantly favorable prognostic factors for OS. Age is in the 
univariate analysis (p=0.018/HR 0.96) and multivariate 
analysis (p=0.01/HR 0.95) the only significantly favorable 
prognostic factor for local relapse free survival.  
Conclusions: The GTV does not have a better prognostic 
value for overall survival and local recurrence free survival in 
patients with locally advanced NSCLC treated with CCRT than 
the PTV (Correlation factor =0.94). 
A cut off point for overall survival was found for GTV 77 cc 
and PTV 390 cc.  
Reference: 
Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. 
Tumor volume combined with number of positive lymph node 
stations is a more important prognostic factor than TNM 
stage for survival of non-small-cell lung cancer patients 
treated with (chemo) radiotherapy. Int J Radiat Oncol Biol 
Phys 2008; 80(4): 1039-1044 
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Purpose/Objective: When formulating radiation treatment 
plans, it has long been assumed that tumor doses should be 
kept homogeneous throughout the tumor in order to 
maximize the likelihood of tumor control. This has lead to 
the widespread adoption of 'D95' as the standard plan-quality 
metric. However, the optimization of this parameter is often 
achieved at the expense of competing dose-volume metrics, 
putting the patient at increased risk of normal tissue 
toxicities despite scant clinical data to support the need for 
dose homogeneity, and mounting biological evidence against 
it. With this in mind, we set out to derive a novel, 
mechanistically-derived metric which accurately derives 
tumor control probabilities from each patient's unique dose 
distributions and fractionation schedules: 'generalized tumor 
dose' (gTD). 
Materials and Methods: The gTD metric was inspired by 
Niemierko's concept of gEUD, which applies a generalized-
mean term ('a') to the dose distribution over the structure of 
interest. Here we apply the same concept, however 
incorporating it into a dose-effect model mechanistically 
derived from known tumor radiobiology, and accounting for 
each patient's unique dosing, fractionation schedule, and 
tumor characteristics. In effect, the derived gTD metric 
reflects the level of absolute cell survival within the tumor, 
subject to the 'a'-based relative weighting of the high or low 
end of the dose distribution. Using parameter optimization 
methods on clinical lung tumor data from two institutional 
cohorts (NKI: N=266 & WUSTL: N=50), we tested the current 
assumption that outcome (local control/failure at last 
followup) is determined by the sum of independent dose 
effects to tumor sub-volumes. 
Results: 
 
Fitting model parameters to the combined cohort data using 
both log-likelihood and actuarial methods, we were able to 
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derive optimized α and α /β of 0.3Gy-1 and 6Gy, respectively. 
We also found a generalized mean value of a=-1.7 (95% 
confidence interval upper bound=-0.1), which produces the 
best performing gTD predictive metric (Fig.). 
Conclusions: A negative 'a' value suggest that areas of low 
cell survival (high dose) play a driving role in determining 
whether local control is achieved, regardless of dose 
homogeneity. In this first known case of multi-institutional 
investigation of case-specific treatment effects, we 
demonstrated the utility and superior predictive power of 
this novel, biologically-inspired dose-metric. 
   
PO-0673   
Stereotactic body radiotherapy for histopathologically 
confirmed vs. presumed early stage NSCLC 
S. Rehman1, M. Roach1, D. Mullen1, T. DeWees1, J. Bradley1, 
C. Robinson1 
1Washington University Medical Center, Radiation Oncology, 
St. Louis, USA  
 
Purpose/Objective: Medically inoperable early stage non-
small cell lung cancer (NSCLC) is frequently treated with 
stereotactic body radiotherapy (SBRT). As this patient 
population is often frail, not only is surgery a potential 
morbid procedure, but obtaining a pathologic diagnosis of 
cancer may be risky as well. It is becoming more common to 
treat patients empirically with growing, positron emission 
tomography (PET) avid lung nodules with SBRT. This study 
looked to compare outcomes between patients with a 
histopathologic diagnosis of cancer compared to patients 
without a diagnosis. 
Materials and Methods: A retrospective review of patients 
enrolled on a prospective IRB-approved registry from 2004 to 
2013 was conducted. Patients with a non-diagnostic biopsy or 
no attempted biopsy were considered to lack a 
histopathologic diagnosis. Patients with synchronous cancers 
or prior invasive malignancy within 2 years of SBRT were 
excluded. Kaplan-Meier curves for local control (LC), 
progression-free survival (PFS), recurrence-free survival 
(RFS), and overall survival (OS) were created by Wilcoxon 
analysis. Patients were evaluated for risk factors predicting 
for LC, PFS, RFS, and OS using Cox regression. 
Results: A total of 427 patients were included in the analysis. 
Median age was 74 years old with a median follow-up of 17 
months (range, 0.2 to 105 months). Of all patients, 332 (78%) 
underwent biopsy confirming diagnosis of malignancy, with 
124 (37%) patients with adenocarcinoma, 98 (30%) patients 
with squamous cell, 98 (30%) patients with NSCLC not 
otherwise specified, and 12 (4%) patients with other 
histologies. Ninety-five patients (22%) were treated 
empirically for suspected lung cancer, of which 92 (97%) were 
staged with PET/CT. Patients treated without a diagnosis 
were more likely to have a prior history of cancer, smaller 
tumors, lower BMI, and a lower PET standardized uptake 
value maximum compared with patients with a diagnosis. 
There was no difference between the groups at baseline with 
regard to age, race, gender, smoking status, Charlson 
comorbidity score, KPS, central location, use of mediastinal 
staging, or use of PET/CT staging. For the entire cohort, 2 
year LC, PFS, RFS and OS was 91%, 47%, 64% and 61%, 
respectively. There was no difference in LC, PFS, RFS, and OS 
between patients with and without biopsy. On multivariate 
analysis, factors predictive for improved OS included KPS ≥70 
{hazard ratio (HR) 0.552 [95% confidence interval (CI), 0.383-
0.796, p=0.005]}, larger CT size of tumor [HR 1.195 (95% CI, 
1.033-1.383), p=0.003] and post-treatment CT scan showing 
partial or complete response [HR 0.399 (95% CI, 0.164-0.968, 
p=0.012)]. 
Conclusions: In carefully selected patients without a biopsy, 
SBRT results in comparable survival and tumor control 
compared with patients treated with a biopsy. 
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Purpose/Objective: To identify prognostic factors for brain 
relapses. A secondary analysis of a prospective randomized 
trial of definitive radiochemotherapy (RT/CT) compared with 
neoadjuvant RT/CT+surgery was performed. 
Materials and Methods: Pts with pathologically proven 
operable IIIA(N2) / selected IIIB NSCLC received 3 cycles 
cisplatin/paclitaxel and neoadjuvant chemoradiotherapy to 
45 Gy (1.5 Gy bid/ concurrent cisplatin/ vinorelbine). Pts 
were reevaluated within an interdisciplinary panel during last 
week of RT/CT. Operable pts were randomized either to 
definitive RT/CT (arm A: risk- adapted boost to 65/71 Gy at 2 
Gy per fraction without break and concurrent 
cisplatin/vinorelbine) or surgery (arm B). Depending on 
institutional policy, PCI could be applied after completion of 
chemotherapy. 
Results: Between 1/2004 and 8/2012, 246 pts (70 F/176 M; 
stages, 75 T1-3 N2 / 80 T4 N0-1/ 91 T4 N2 or T1-3N3; 
histology, 95 SCC / 107 ADC / 44 other) were enrolled from 5 
centers, 161 patients were randomised (arm A: 80 pts, arm 
B:81 pts). Brain relapse as part of any relapse was observed 
in 33 randomised pts, isolated brain failures were detected in 
23 pts. Freedom from isolated brain relapse (FFIBR) at 2 
years was 84 (78-90)% for all patients, arm A 83 (73-93)%, 
arm B 81 (71-91)%. 42 pts recieved prophylactic cranial 
irradiation. PCI did not influence the incidence of isolated 
brain relapses (FFIBR at 2 years with or without PCI: 84 (70-
98)% vs 81 (73-89)%, p=0.93). Factors associated with a higher 
incidence of isolated brain relapses in univariate analysis 
were female gender (FFIBR at 2 years: 89 (81-97)% (male) vs 
72 (58-86)%, p=0.03) and TN-stage subgroup (FFIBR at 2 
